Economy/Home · Economy

Alteogen Postpones Schedule for Merger with Alteogen Biologics... Merger Date Moved to February 16, 2027

Alteogen announced on the 12th via a regulatory filing that it will change the schedule for absorbing and merging its subsidiary Alteogen Biologics. According to the amended filing, the merger date, originally scheduled for December 29, 2026, has been postponed to February 16, 2027. ■ Other Merger-

Oseong Kwon
Staff Reporter
4 min read
Alteogen Postpones Schedule for Merger with Alteogen Biologics... Merger Date Moved to February 16, 2027
CBC News

Alteogen announced on the 12th via a regulatory filing that it will change the schedule for absorbing and merging its subsidiary Alteogen Biologics. According to the amended filing, the merger date, originally scheduled for December 29, 2026, has been postponed to February 16, 2027.

■ Other Merger-Related Schedule Changes

The key changes announced in the amended filing are as follows.

• Scheduled general shareholders' meeting date: November 27, 2026 → January 15, 2027 • Creditor objection period: November 27 – December 28, 2026 → January 15 – February 15, 2027 • Merger date: December 29, 2026 → February 16, 2027 • Scheduled merger registration date: December 30, 2026 → February 17, 2027

■ Merger Structure, Ratio, and New Share Issuance

The merger will proceed as a absorption of Alteogen Biologics by Alteogen. Following the merger, Alteogen will remain as the surviving company, while Alteogen Biologics will be dissolved.

The merger ratio has been set at 0.1679581 shares of Alteogen Biologics per one common share of Alteogen. The merger valuation is 261,345 won per share for Alteogen and 43,895 won per share for Alteogen Biologics. A total of 600,047 new common shares will be issued through the merger.

■ Purpose: Securing Financial Stability and Building a FIBCO Structure

The company stated that the purpose of the merger is to secure financial stability, proactively mitigate business and financial risks, and enhance operational efficiency through a restructuring of its business organization. In particular, the company plans to consolidate its business structure—currently divided between R&D/manufacturing and clinical/regulatory/marketing—into a single entity, establishing a fully integrated bio-pharmaceutical company (FIBCO) business system spanning from new drug discovery to commercialization.

However, the company noted that the revised merger schedule is a tentative schedule as of the filing date, and it may change again depending on approvals and permits under relevant laws and regulations, as well as consultations with relevant authorities.

Oseong Kwon
Staff Reporter

CBC Globe publishes verified stories with editorial review, source checks, and tenant-specific publication standards.